- Home
- PMO vs TNGX Comparison
PMO vs TNGX Comparison
Compare PMO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMO | TNGX |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.3M | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PMO | TNGX |
|---|---|---|
| Price | $10.41 | $8.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 99.0K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | N/A | ★ $66,501,000.00 |
| Revenue This Year | N/A | $52.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.38 | ★ N/A |
| Revenue Growth | N/A | ★ 53.29 |
| 52 Week Low | $8.57 | $1.03 |
| 52 Week High | $10.68 | $11.20 |
Technical Indicators
Market Signals| Indicator | PMO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 45.46 |
| Support Level | $10.31 | $8.42 |
| Resistance Level | $10.47 | $8.98 |
| Average True Range (ATR) | 0.09 | 0.55 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 25.81 | 22.47 |
Price Performance
Historical ComparisonAbout PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.